Mark Lazarev, MD
Gastroenterology · Baltimore, MDNPI 1104094739
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Johnson & Johnson at 35.6% of the total. Reporting peaked in 2024 at $7,365 and has fallen 65.4% since, to $2,545 in 2025.
Across 559 payments — averaging $33.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Janssen Global Services, LLC$4K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Pfizer$833
- Bristol Myers Squibb$549
- plus $4K from 31 others
Across 11 payments — averaging $9645.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$106K
What the payments were for
- Consulting fees$7,68541%
- Food & beverage$11,00159%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 136 | $6,666 |
| Janssen Global Services, LLC | 1 | $3,515 |
| AbbVie | 124 | $2,019 |
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $1,610 |
| Pfizer | 51 | $833 |
| Bristol Myers Squibb | 32 | $549 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $420 |
| Madrigal Pharmaceuticals | 8 | $287 |
| Braintree Laboratories, Inc. | 7 | $240 |
| Celltrion USA Inc. | 21 | $235 |
| Ipsen Biopharmaceuticals, Inc | 8 | $200 |
| Boehringer Ingelheim | 7 | $178 |
| Daiichi Sankyo Inc. | 7 | $174 |
| Sandoz | 6 | $158 |
| Shield Therapeutics Inc | 6 | $138 |
| Lilly USA, LLC | 6 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Sanofi | 4 | $115 |
| UCB, Inc. | 6 | $103 |
| Merck | 5 | $103 |
| Intercept Pharmaceuticals, Inc. | 4 | $95 |
| Ferring Pharmaceuticals Inc. | 4 | $79 |
| QOL Medical, LLC | 3 | $74 |
| Phathom Pharmaceuticals, Inc. | 3 | $71 |
| Ardelyx, Inc. | 3 | $69 |
| Orphalan Inc | 3 | $68 |
| Aimmune Therapeutics, Inc. | 2 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $60 |
| Gilead | 2 | $49 |
| Biocon Biologics Inc | 1 | $25 |
| Organon | 3 | $25 |
| Amgen | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,707 in reported general payments places this provider in the 85th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 164 | $4,785,637 |
| Skyrizi On-BodyRisankizumab-Rzaa | 23 | $429,130 |
| RemicadeInfliximab | 36 | $324,250 |
| Humira(Cf) PenAdalimumab | 12 | $300,541 |
| Humira(Cf)Adalimumab | 22 | $185,332 |
| Humira PenAdalimumab | 13 | $183,151 |
| Mesalamine | 93 | $85,920 |
| InflectraInfliximab-Dyyb | 11 | $71,729 |
| AprisoMesalamine | 11 | $10,822 |
| Mesalamine ErMesalamine | 19 | $5,498 |
| Azathioprine | 17 | $1,518 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 41 | $1,317 |
| Budesonide DrBudesonide | 15 | $1,246 |
| Colestipol Hcl | 12 | $943 |
| Omeprazole | 54 | $788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $6,666 | $5,109,887200 claims |
| AbbVieHumira(Cf) | $2,019 | $185,33222 claims |
| PfizerInflectra | $833 | $71,72911 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso | $420 | $10,82211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Baltimore
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Raymond CrossBaltimore$341K
- Paul ThuluvathBaltimore$231K
- Niraj JaniBaltimore$214K
- Aminur KhanBaltimore$118K
- Eric GoldbergBaltimore$110K
- Saowanee NgamruengphongBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.